My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
ASAP Blog
Blog Home All Blogs
Welcome to ASAP Blog, the best place to stay current regarding upcoming events, member companies, the latest trends, and leaders in the industry. Blogs are posted at least once a week; members may subscribe to receive notifications when new blogs are posted by clicking the "Subscribe" link above.

 

Search all posts for:   

 

Top tags: alliance management  alliances  collaboration  partnering  alliance  partner  partners  partnerships  alliance managers  ecosystem  alliance manager  The Rhythm of Business  partnership  Jan Twombly  Vantage Partners  biopharma  governance  Eli Lilly and Company  strategy  Strategic Alliance Magazine  collaborations  IBM  cloud  IoT  strategic alliances  ASAP BioPharma Conference  healthcare  innovation  Christine Carberry  Cisco 

Revamped Bayer Alliance Practice Relieves Partnering Headaches

Posted By Jon Lavietes, Saturday, August 29, 2020

Five years ago, Bayer’s R&D alliance management group knew it needed changes. Even though its core partners were happy in their collaborations with the 150-year-old pharmaceutical and over-the-counter medicine institution, the external perception in the broader pharma community landed in the lower tier, according to its internal research.

The R&D group embarked on changes to its alliance practice in order to improve its function and achieve three larger organizational objectives: 1) deepen the company’s understanding of the mechanisms of diseases that were getting increasingly complex; 2) broaden its drug portfolio into new modalities, technology, and external innovation; and 3) make its operating model more flexible, in general.

Bayer was contending with a variety of changes in its operating environment. First, the number of alliances—and the number of people from outside the organization working on Bayer initiatives—was growing fast. Moreover, the company was engaging in new types of collaborations, such as digital health partnerships, in which it found itself in the unfamiliar position of being the inexperienced party. Partners increasingly had their own alliance networks playing roles in Bayer collaborations, which added a new layer of complexity to the management of these collaborations.

Two Bayer executives shared the story of the company’s still-in-progress alliance management makeover in an on-demand 2020 ASAP Global Alliance Summit session, “Enabling Strategic Change—Cultural and Alliance Capability Development,” which took viewers through the internal and external changes that were made in order to modernize its alliance practice and improve its standing within the broader pharma partner community.

Bayer’s New Training Regimen Comes Up ACEs

The first step in upgrading Bayer’s organizational alliance capability was to overhaul alliance manager training. More specifically, the practice instituted highly tailored individual plans; executives were coming to alliance management from a variety of areas (e.g., marketing, R&D, business development, etc.) and each had different strengths, weaknesses, and bodies of knowledge.

Bayer complemented this individualized training with its Alliance Community Excellence (ACE) initiative, which brought in outside experts, sometimes from unusual places, to hold court on facets of alliance management. Michael Kennedy, PhD, director of strategic alliances in Bayer’s Business Development & Licensing group, spoke of one instance where a former FBI trainer taught alliance managers how to identify and neutralize lying and deceit. The ACE program also placed an intense focus on external networking, including deepening the alliance group’s interaction with the ASAP community. As part of the ACE program, the alliance management practice also set up a help line so that nobody in the organization felt like they were on an island. 

“Who are you going to call? It’s not Ghostbusters. It needs to be somebody within our broad alliance community that people can call, either as an alliance manager running into some challenging topics and wanting to discuss it or somebody on an alliance team. They can pick up the phone and call one of us alliance managers for help,” said Kennedy. 

Complementary Principles, Competencies Go Hand in Hand

Bayer structured its training into six core competency categories: 1) alliance know-how, 2) collaboration, 3) joint problem solving, 4) organizational agility, 5) flexibility, and 6) conflict management, and developed curriculum for executives of different levels (e.g., rank-and-file team members vs. alliance leaders). Each of these areas consisted of three to five individual skills. Kennedy explained that the organization sees synergy between these areas and that they can be broken down into three complementary pairs—organizational agility helps optimize alliance know-how, flexibility aids collaboration, and conflict management is an inevitable part of joint problem solving.

Kennedy walked the virtual audience through a set of foundational principles grouped into two broad categories—1) “Establish,” which dealt with structure and process, and 2) “Practice,” guidance around mindset and culture—that similarly went hand in hand with each other. Each alliance needs resources—namely, the right people, capacity, and investment—but they are useless if partners don’t have access to Bayer leaders. (Resources represent an “Establish” principle, while access comes from the “Practice” category.) Governance, another “Establish” principle, is nothing without alignment, which Kennedy defined in this context as “speaking with one voice.” Communication, both in terms of timing and consistency, to partners and the public at large is paramount, but problem-solving capabilities will eventually be necessary when it breaks down. For years, Bayer struggled to acknowledge partners’ differences, but in recent years the company has strived to safeguard the value joint initiatives are expected to bring to allies. Carry out all of these principles, and Bayer partnerships will generate execution and trust.

“[Execution and trust] really are the foundational pieces of our partnering principles,” said Kennedy.

A New Alliance Culture: Play to Win vs. Playing It Safe

Of course, principles and competencies only go so far if a corporate culture isn’t designed to optimize them. Bayer had a lot of work to do in this area, according to Christoph Huwe, CSAP, PhD, director of strategic alliance development for R&D Open Innovation & Digital Technologies at Bayer. First, the company had to stop operating in silos. To that end, it adopted the mantra “assets over function,” recounted Huwe in describing the new collaborative mindset that encouraged employees engaged in alliances to prioritize activities that were necessary to advance a drug candidate to a clinic or patient. Bayer relaxed its traditionally “top-down” command-and-control model, so that its employees had the freedom to execute accordingly without having to run every decision up the ladder within the company.

Bayer similarly loosened its risk-averse ways to enable the alliance practice to “play to win and learn over playing it safe”—according to Huwe, the organization was previously less inclined to make mistakes. From a strategic standpoint, Bayer’s mentality switched to one of “science over process.” That is, instead of trying to force a drug to work for a preplanned indication, it would follow the science and pursue another indication if initial research showed the asset was better suited for it.  

Cards on the Table: Alliance Game Players Learn Practice’s Four Pillars

Of course, culture starts at the top, so the alliance practice puts its senior leaders through rigorous team and individual training to lead by example and accept what Huwe characterized as “very candid feedback about inconsistencies” in what they preach and what they do vis-à-vis partner initiatives. Midlevel management retraining was also critical, according to Huwe, since the majority of people working on alliance engagements reported to executives at this level.

Since senior executives usually developed the company’s alliance strategy in advance, it was up to the alliance practice to rebrand itself and communicate the new vision to the rest of the organization through “game-ified” cross-functional team-based exercises. For example, the alliance practice created a board game that was divided into the four pillars of Bayer’s internal culture—collaboration, experimentation, customer focus, and trust. About a dozen players would break into smaller groups where they would be asked to discuss whether actions detailed on playing cards were “blockers or drivers” of these four cultural mainstays. The smaller groups would ultimately reconvene to share and discuss their findings in one large discussion.

Huwe said the alliance management team also instituted new “health-check–style surveys,” which measured “awareness, agreement, involvement, and impact,” to make sure the new culture was taking root. Huwe placed a special emphasis on the “agreement” piece.

“You have to have an understanding if the organization is really on board because if they aren’t you have to think of ways to get them there,” he said. “Senior leadership will be much ahead of the rest of the organization in their agreement to the process, so they need to understand that we’re not quite there yet, and they have to continue to work with the rest of the organization to get there.”

Out of Its Comfort Zone and into Global Pharma Networks

Bayer also embarked on several new measures to improve its reputation as a partner externally.

“We’re trying to leverage the partner’s strengths and capabilities and not trying to turn them into more like Bayer. This is causing us to get out of our comfort zone and expand the way that we think and the way that we work with partners,” said Kennedy.

Case in point, Bayer previously had a company policy limiting press releases to deal signings and phase 3 or later. However, the company has recently relaxed that internal standard to accommodate partners that were eager to issue announcements detailing successes in earlier stages of the drug development cycle. In addition, the normally process-driven company has taken steps to become more flexible. For example, it cut the number of steps in its governance process to approve a deal by more than half.

Bayer has in some cases chosen to collocate employees at partner sites, and it has also opened up business and innovation centers in regions around the world considered hotbeds of pharmaceutical activity, such as San Francisco, Boston, Osaka, Beijing, Singapore, and Berlin.

“We’re going to where the networks are already existing and not asking people to come to Bayer [headquarters],” said Kennedy, who added that the company can now take partners to these sites to give them an up-close look at Bayer’s affairs.

The company has established effective online platforms, hosted more partnering events, and increased its conference presence, even bringing actor Michael J. Fox to one show to speak about the company’s efforts around Parkinson’s disease. Today, half of the company’s top 10 products come from partner initiatives, accounting for more than half of Bayer’s revenues.

The opening slide of Kennedy’s roadshow presentation now says it all: “Bayer is a partnering company.”

Huwe and Kennedy had more to share about Bayer’s partnering transformation, so make sure to use your Summit registration information to catch the full presentation in the Summit portal. While you’re there, peruse more than 20 other insightful sessions from the first-ever virtual ASAP Global Alliance Summit.

Tags:  alliances  Bayer  Christoph Huwe  collaborations  Digital Technologies  Global Pharma Networks  Michael J. Fox  Michael Kennedy  Open Innovation  partnering  partners  strategic  transformation 

Share |
PermalinkComments (0)
 

ASAP’s New “Quick Takes” Explore Impact of IoT and Ecosystem Partnering—and Proves to Be a Highly Successful Format for Engaging 2016 Summit Participants

Posted By Cynthia B. Hanson & John DeWitt, Friday, March 18, 2016

Some forms of communication are more effective than others. The “TED Talks” speaking format, for example, has drawn significant numbers of interested viewers for over 30 years. That is why ASAP decided to introduce its new “ASAP Quick Takes,” patterned after the “TED Talks,” unveiling them for the first time at the 2015 ASAP Biopharma Conference, and again, at the 2016 ASAP Global Alliance Summit. 

The talks were a big hit and garnered lots of positive feedback. Such short talks are successful for several reasons: The message is sometimes simple, imaginative, and an easy take-away; the time limit of about 20 minutes forces speakers to distill the main points, which more-readily captivates the audience. 

Take, for example, John Bell’s “Quick Takes” talk where the marketing executive for strategy development at Johnson & Johnson Consumer Health advised a collaborative approach: “Play in the sandbox. We are sitting on massive scale of opportunity to work in open innovation,” he said. “The toys must be shared. You can’t have it all your way, and you must behave yourself,” he added, while outlining the rules for success in today’s partnering environment. “Today, it’s a whole playground! Amusement parks, even. You can do many things [with] so many kids to play with. Which one would you choose, and why would they play with you?” he asked provocatively, prompting the audience to join him in the creative box for 20 minutes. 

Bell’s invitation was a terrific precursor to the talk by Larry Walsh, CEO of The 2112 Group and a well-known journalist, who asked the audience to join him in a virtual chess game. Strategy is a key component of success, he said. “Strategy is about making choices. If you fail to make choices, you often put yourself at risk,” he continued. “Lots of businesses say they make choices, but they are consumed by revenue generation and don’t discriminate between good and bad decisions. They also fail to anticipate. This is where surveying the landscape equates with chess. If you don’t survey the landscape and understand your competition, you cannot anticipate what the opposition will do,” he noted. Among other things, “you need to lay traps and position assets to create advantages.” 

Think ahead and read the board, he advised. Not only what you are going to do, but what your opponent is going to do. Chess helps you to play by the rules and take responsibility for your actionsto problem-solve in an uncertain environment.” 

Another “Quick Talks” speaker, Anne Nelson of IBM Watson, threw out an elaborate blueprint for success for IoT multi-partnering. IBM’s new business unit, formed in 2014, has seen astronomical growthsome 500 new partners in just two years. The IBM Watson Group provides over 30 services that partners can write applications against or leverage to improve applications. “What did you tweet over the last two weeks?” she asked the audience to recall. “Watson can provide personality insights from those tweets” and generate different coupons for discounts depending on that profile. “We are opening the platform to partners on data as well,” she replied. ‘This platform is the only one in the industry today with this many apps.” 

What’s the value for partners in alliances with IBM in the Watson ecosystem? “We’re the number one B2B brand, Watson has 70 percent unaided awareness—so brand is going gangbusters in terms of value to partners,” said Nelson, who was recruited to IBM Watson Group from IBM’s direct sales organization in January of 2015. “We have over 40,000 IBM sellers who touch millions of accounts,” she noted. 

For a longer-term view of success, Marcus Wilson, president and co-founder of Anthem’s real-world research subsidiary, HealthCore, Inc., spoke about his 20-plus years building healthcare partnerships. The key component is building trust, he said. His experience included pioneered the emergence of physician and patient education and clinical decision support services based upon real-world data. Wilson’s experience exemplifies the “kind of creativity and entrepreneur skill increasingly required when we are reinventing what we are doing all the time,” said Jan Twombly, CSAP, ASAP chairman of programming, and president of The Rhythm of Business, who prefaced the talks as moderator. 

As an entrepreneur and “intrapreneur,” Wilson shared several formative personal experiences, starting as a young clinical pharmacist doing his residency at a Blue Cross/Blue Shield of Delaware health center. “Influence is everything,” Wilson emphasized. “I had no power to prescribeI would have to walk into physicians’ offices and convince them that it was their idea to treat the way they should. I had to influence the healthcare center to offer all these new services—which eventually became incredible force for us.” Similarly, he said, “We met with FDA 10 years ago about real-world evidence. They said, that’s great, but this stuff is voodoo science.” Thanks to influence—reinforced by lots of data—“it’s becoming much more mainstream today.” 

You can read individual blog posts about these “Quick Takes” talks on our website at http://www.strategic-alliances.org/blogpost/1143942/ASAP-Blog.

Tags:  alliances  Ann Nelson  ASAP Quick Takes  assets  B2B brand  collaborative  healthcare partnerships  Heathcore Inc.  IBM Watson  IoT  John Bell  Johnson & Johnson Consumer Health  Larry Walsh  Marcus Wilson  multi-partnering  open innovation  partnering environment  problem solve  strategy  TED Talks  The 2112 Group 

Share |
PermalinkComments (0)
 
For more information email us at info@strategic-alliances.org or call +1-781-562-1630